secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-08-22T23:59:59+00:00
Accession:  0001193125-23-217481
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio and WuXi ATU expand GMP manufacturing for CABA-201; dedicated suite for commercial readiness
--------------------------------------------------------------------------------

- WuXi ATU to provide GMP manufacturing for CABA-201, including commercial readiness, under expanded work orders.
- Dedicated suite added for CABA-201 and MuSK-CAART programs; initial 18-month term with two 18-month extensions at Cabaletta's option.
- Termination fee revised to $1.08M if both programs terminated; Cabaletta can terminate with 6 months' notice.
- Expansion supports planned parallel Phase 1/2 trials in SLE and myositis, plus potential late-stage trials.
- Cabaletta cites capital-efficient manufacturing strategy and prior successful collaboration with WuXi ATU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523217481/0001193125-23-217481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523217481/d524786d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-217481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer